After achieving a complete response in multiple myeloma after one year of bortezomib (Velcade), which next agent is appropriate given concurrent diarrhea and peripheral neuropathy?

Carfilzomib-Based Regimen is the Optimal Next Choice

After achieving complete response with bortezomib (Velcade) for one year, carfilzomib combined with lenalidomide and dexamethasone (KRd) or carfilzomib with dexamethasone (Kd) represents the best next-line therapy in the setting of diarrhea and peripheral neuropathy. Carfilzomib is a second-generation proteasome inhibitor specifically designed to minimize neurotoxicity while maintaining proteasome inhibition efficacy 1.

Rationale for Carfilzomib Selection

The key advantage of carfilzomib over continuing bortezomib or switching to other proteasome inhibitors is its dramatically reduced peripheral neuropathy profile. Multiple guidelines consistently emphasize that carfilzomib is "associated with a low risk of neurotoxicity" with "no grade ≥3 neuropathy observed" in clinical trials 1, 2. This is critical given your patient's existing neuropathy from bortezomib.

Evidence Supporting Carfilzomib

The ENDEAVOR trial demonstrated that Kd (carfilzomib 56 mg/m² with dexamethasone) achieved superior progression-free survival compared to bortezomib-dexamethasone (HR 0.53), with the benefit observed across all patient subgroups including first relapse 3. While carfilzomib has different toxicities (hypertension, dyspnea, cardiac events, acute renal failure), it notably causes fewer cases of peripheral neuropathy 3.

Recent real-world data from 2026 specifically addressed your clinical scenario: transitioning from first-line bortezomib to carfilzomib due to intolerance (particularly ≥grade 1 painful peripheral neuropathy) resulted in significant improvement. At 4 months post-transition, all patients' peripheral neuropathic pain symptoms had disappeared, with 60% achieving complete resolution 4. Importantly, this transition also deepened remission, with complete response rates increasing from 30.4% to 69.5% 4.

Specific Regimen Recommendations

First Choice: Carfilzomib + Lenalidomide + Dexamethasone (KRd)

• Dosing: Carfilzomib 20 mg/m² (cycle 1) then 27 mg/m² IV on days 1,2,8,9,15,16; lenalidomide 25 mg oral days 1-21; dexamethasone 20 mg on days of and after carfilzomib 3
• Cycle: 28-day cycles
• Advantages: Highest response rates, maintains immunomodulatory drug backbone

Second Choice: Carfilzomib + Dexamethasone (Kd)

• Dosing: Carfilzomib 56 mg/m² IV days 1,2,8,9,15,16 (20 mg/m² days 1,2 cycle 1 only); dexamethasone 20 mg days 1,2,8,9,15,16,22,23 3
• Cycle: 28-day cycles
• Advantages: Simpler regimen if lenalidomide exposure is a concern

Managing Diarrhea

The diarrhea is likely bortezomib-related and should improve with discontinuation. However, if diarrhea persists or worsens with carfilzomib:

• Carfilzomib itself has lower gastrointestinal toxicity than bortezomib 3
• If lenalidomide is included (KRd), monitor as lenalidomide can cause diarrhea
• Consider dose modifications or supportive care with antidiarrheals

Critical Monitoring with Carfilzomib

While carfilzomib spares peripheral nerves, you must monitor for:

• Cardiovascular toxicity: Hypertension (most common), cardiac failure, dyspnea 3
• Renal function: Acute renal failure risk, requires pretreatment hydration 3
• Infusion reactions: First infusion requires 6.5 hours, subsequent infusions 3.5 hours 3

Alternative Consideration: Daratumumab-Based Regimens

If carfilzomib is unavailable or contraindicated (e.g., significant cardiac disease), daratumumab with lenalidomide and dexamethasone (DRd) is an excellent alternative 3. Daratumumab adds no significant peripheral neuropathy and has shown impressive efficacy (HR 0.39 for PFS in the CASTOR trial when combined with bortezomib-dexamethasone) 3. However, given your patient already has neuropathy, avoiding all proteasome inhibitors temporarily with DRd would be reasonable.

Common Pitfall to Avoid

Do not simply reduce bortezomib dose or switch to subcutaneous/weekly bortezomib administration. While these modifications reduce neuropathy incidence 5, 2, your patient has already developed symptomatic neuropathy after one year of therapy. The evidence shows that in-class transition to carfilzomib provides both symptom relief AND deepened remission 4, making it superior to dose-modified bortezomib continuation.

The treatment discontinuation rates due to adverse events were identical between carfilzomib and bortezomib arms in ENDEAVOR despite different toxicity profiles 3, confirming that carfilzomib's toxicities are manageable and should not deter its use in this neuropathy-complicated scenario.